Finding the right reimbursement model for gene therapiesWith cell and gene therapies growing more and more important to healthcare, we sat down with Debbie Warner, Share XFinding the right reimbursement model for gene therapieshttps://pharmaphorum.com/views-and-analysis/finding-the-right-reimbursement-model-for-gene-therapies/
Did cancer clinical trials stay on track at ASCO 2019?Chicago is recovering after 40,000 oncologists and cancer experts descended on the city for this year’s ASCO conference. Share XDid cancer clinical trials stay on track at ASCO 2019?https://deep-dive.pharmaphorum.com/magazine/oncology-asco-2019/kantar-cancer-clinical-trials/
ASCO 2019 round-upWith the American Society of Clinical Oncology (ASCO) conference over for another year, Richard Staines presents a round-up Share XASCO 2019 round-uphttps://pharmaphorum.com/spotlight/asco-2019-and-the-future-of-oncology/asco-2019-round-up/
ASCO 2019 – Kantar considers MacroGenics’ phase 3 SOPHIA trialKantar analyst Katie Stockstill discusses the results of phase 3 SOPHIA trial that were presented on the last Share XASCO 2019 – Kantar considers MacroGenics’ phase 3 SOPHIA trialhttps://pharmaphorum.com/spotlight/asco-2019-and-the-future-of-oncology/kantar-macrogenics-phase-3-sophia-trial/
ASCO 2019 – phase I data generates hope for the futureSometimes interesting stories from the ASCO conference are the phase I data that generates hope for the future. Share XASCO 2019 – phase I data generates hope for the futurehttps://pharmaphorum.com/spotlight/asco-2019-and-the-future-of-oncology/amgen-kras-amg510-phase-i-data/
ASCO 2019 day fiveExclusive live coverage from day five of the American Society of Clinical Oncology’s annual meeting in Chicago. • Share XASCO 2019 day fivehttps://pharmaphorum.com/spotlight/asco-2019-live-coverage/asco-2019-day-five/
ASCO 2019 – Enfortumab comes out fighting in bladder cancerAt ASCO 2019, results were presented from the phase II EV-201 trial, which evaluated antibody drug conjugate (ADC) Share XASCO 2019 – Enfortumab comes out fighting in bladder cancerhttps://pharmaphorum.com/video/asco-2019-enfortumab-bladder-cancer/
ASCO 2019 – Kantar highlights a selection of exciting Phase I and Phase II resultsAt ASCO, a lot of attention is given to the results of the large, clinical practices changing phase Share XASCO 2019 – Kantar highlights a selection of exciting Phase I and Phase II resultshttps://pharmaphorum.com/video/asco-2019-results-clinical-practices-changing-phase-iii-studies/
ASCO 2019 – Kantar debates results from the KEYNOTE-062 trialThere were a number of debate-worthy outcomes from the KEYNOTE-062 trial that was presented at ASCO 2019 in Share XASCO 2019 – Kantar debates results from the KEYNOTE-062 trialhttps://pharmaphorum.com/spotlight/asco-2019-and-the-future-of-oncology/asco-2019-kantar-debate-results-from-keynote-062-trial/
